Clinical Trial News

Insights and updates on ongoing and upcoming clinical trials in neurotech, including recruitment, findings, and innovations from around the globe.

Neuralink

Weekly Signal: 58 | Capital Picks the Smaller Footprint

May 24, 2026

•

5 min read

Weekly Signal: 58 | Capital Picks the Smaller Footprint

Meta's NeuralBench lands; NEO goes commercial

Ricardo Albornoz

Neurotechnology

Weekly Signal: 57 | Three Strategic Bets Emerge in Neurotech

May 9, 2026

•

2 min read

Weekly Signal: 57 | Three Strategic Bets Emerge in Neurotech

Neuralink, SetPoint, ARIA each bet differently

Ricardo Albornoz

Clinical Trial News

Weekly Signal: 55 | CorTec Enters FDA's TAP for Chronic BCIs

Apr 25, 2026

•

2 min read

Weekly Signal: 55 | CorTec Enters FDA's TAP for Chronic BCIs

Plus €40.6M and a stealth exit

Ricardo Albornoz

Neurotechnology

Weekly Signal: 54 | Biohybrid BCI Hits Yale, Cala Clears

Apr 18, 2026

•

2 min read

Weekly Signal: 54 | Biohybrid BCI Hits Yale, Cala Clears

Invasiveness tiers get crowded

Ricardo Albornoz

Closed-loop DBS

Weekly Signal: 53 | CorTec Closes the BCI Loop

Apr 11, 2026

•

8 min read

Weekly Signal: 53 | CorTec Closes the BCI Loop

Plus: organoids go to war

Ricardo Albornoz

Neurotechnology

Weekly Signal: 51 | When the Brain Overcorrects

Mar 28, 2026

•

6 min read

Weekly Signal: 51 | When the Brain Overcorrects

Control, not just signal

Ricardo Albornoz

Closed-loop DBS

Weekly Signal: 50 | The Typing Threshold

Mar 21, 2026

•

14 min read

Weekly Signal: 50 | The Typing Threshold

BCIs Close in on Normal Speed

Ricardo Albornoz

Ethics & Policy

Weekly Signal: 49 | China Wins the BCI Commercial Race

Mar 14, 2026

•

14 min read

Weekly Signal: 49 | China Wins the BCI Commercial Race

The Regulatory Finish Line Just Moved

Ricardo Albornoz

Closed-loop DBS

Weekly Signal: 48 | BCIs Race to First Commercial Products

Mar 8, 2026

•

16 min read

Weekly Signal: 48 | BCIs Race to First Commercial Products

Science Corp. Leads the Pack

Ricardo Albornoz

Closed-loop DBS

Weekly Signal: 47 | Adaptive DBS Gets Its Operating Manual

Mar 1, 2026

•

12 min read

Weekly Signal: 47 | Adaptive DBS Gets Its Operating Manual

Plus: Japan's Stem Cell Gamble

Ricardo Albornoz

Neuroscience

Weekly Signal: 46 | Forecasting Alzheimer's and Fixing EEG's Data Problem

Feb 21, 2026

•

7 min read

Weekly Signal: 46 | Forecasting Alzheimer's and Fixing EEG's Data Problem

Forecasting the Brain's Future

Ricardo Albornoz

Closed-loop DBS

Weekly Signal: 45 | Clinical Signals in Brain Interfaces

Feb 15, 2026

•

6 min read

Weekly Signal: 45 | Clinical Signals in Brain Interfaces

Real-World Decoding Advances

Ricardo Albornoz

Neurotechnology

Weekly Signal: 44 | BCI Rehab Evidence Comes Into Focus

Feb 8, 2026

•

7 min read

Weekly Signal: 44 | BCI Rehab Evidence Comes Into Focus

Poststroke outcomes, coverage signals

Ricardo Albornoz

Neurotechnology

Weekly Signal: 43 | Durability Replaces Demos in Neurotech

Feb 1, 2026

•

6 min read

Weekly Signal: 43 | Durability Replaces Demos in Neurotech

Long-horizon signals emerge

Ricardo Albornoz

Closed-loop DBS

Weekly Signal: 41 | Evidence Tightens Across Neurotechnology

Jan 17, 2026

•

7 min read

Weekly Signal: 41 | Evidence Tightens Across Neurotechnology

Trials, Funding, FDA Signals

Ricardo Albornoz

Neurotechnology

Weekly Signal: 40 | The First Signal of 2026

Jan 11, 2026

•

7 min read

Weekly Signal: 40 | The First Signal of 2026

Foundations, funding, and clarity

Ricardo Albornoz

Neurotechnology

Weekly Signal: 39 | Clinical Proof, Clearer Signals

Dec 27, 2025

•

4 min read

Weekly Signal: 39 | Clinical Proof, Clearer Signals

Neuromodulation and measurement advance

Ricardo Albornoz

Neurotechnology

Weekly Signal: 38 | When BCIs Leave the Lab

Dec 20, 2025

•

6 min read

Weekly Signal: 38 | When BCIs Leave the Lab

Regulation, reality, deployment

Ricardo Albornoz

Neurotechnology

Weekly Signal: 37 | Neurotech Moves Home and Wireless

Dec 13, 2025

•

8 min read

Weekly Signal: 37 | Neurotech Moves Home and Wireless

BCIs, Stimulation, and Scale

Ricardo Albornoz

Neurotechnology

Weekly Signal: 36 | ALS Trials Accelerate, Ultrasound Advances, MRI Goes Bedside

Dec 6, 2025

•

7 min read

Weekly Signal: 36 | ALS Trials Accelerate, Ultrasound Advances, MRI Goes Bedside

Critical milestones in modern neurotech

Ricardo Albornoz

Neurotechnology

Weekly Signal: 35 | Ultrasound, BCIs, and the Battle for Brain Data

Nov 29, 2025

•

7 min read

Weekly Signal: 35 | Ultrasound, BCIs, and the Battle for Brain Data

Breakthroughs in Brain Signals and Safety

Ricardo Albornoz

Neurotechnology

Weekly Signal: 34 | Speech BCIs, Craving Circuits, and Mental Privacy

Nov 22, 2025

•

6 min read

Weekly Signal: 34 | Speech BCIs, Craving Circuits, and Mental Privacy

Signals shaping neurotech’s future

Ricardo Albornoz

Ethics & Policy

Weekly Signal: 33 | Mind Captioning, Neural Barcodes, and Neurotech Ethics

Nov 15, 2025

•

7 min read

Weekly Signal: 33 | Mind Captioning, Neural Barcodes, and Neurotech Ethics

Decoding, biomarkers, and governance

Ricardo Albornoz

Neurotechnology

Weekly Signal: 31 | FcRn Trials, Neuromodulation Breakthroughs, and Neuro-Rights

Nov 1, 2025

•

7 min read

Weekly Signal: 31 | FcRn Trials, Neuromodulation Breakthroughs, and Neuro-Rights

Clinical data, funding moves, and policy shifts

Ricardo Albornoz

Closed-loop DBS

Weekly Signal: 29 | Synapses, Stimulators & Safeguards

Oct 18, 2025

•

5 min read

Weekly Signal: 29 | Synapses, Stimulators & Safeguards

Mechanisms, markets, and mental privacy

Ricardo Albornoz

Clinical Trial News

Weekly Signal: 58 | Capital Picks the Smaller Footprint

Weekly Signal: 57 | Three Strategic Bets Emerge in Neurotech

Weekly Signal: 55 | CorTec Enters FDA's TAP for Chronic BCIs

Weekly Signal: 54 | Biohybrid BCI Hits Yale, Cala Clears

Weekly Signal: 53 | CorTec Closes the BCI Loop

Weekly Signal: 51 | When the Brain Overcorrects

Weekly Signal: 50 | The Typing Threshold

Weekly Signal: 49 | China Wins the BCI Commercial Race

Weekly Signal: 48 | BCIs Race to First Commercial Products

Weekly Signal: 47 | Adaptive DBS Gets Its Operating Manual

Weekly Signal: 46 | Forecasting Alzheimer's and Fixing EEG's Data Problem

Weekly Signal: 45 | Clinical Signals in Brain Interfaces

Weekly Signal: 44 | BCI Rehab Evidence Comes Into Focus

Weekly Signal: 43 | Durability Replaces Demos in Neurotech

Weekly Signal: 41 | Evidence Tightens Across Neurotechnology

Weekly Signal: 40 | The First Signal of 2026

Weekly Signal: 39 | Clinical Proof, Clearer Signals

Weekly Signal: 38 | When BCIs Leave the Lab

Weekly Signal: 37 | Neurotech Moves Home and Wireless

Weekly Signal: 36 | ALS Trials Accelerate, Ultrasound Advances, MRI Goes Bedside

Weekly Signal: 35 | Ultrasound, BCIs, and the Battle for Brain Data

Weekly Signal: 34 | Speech BCIs, Craving Circuits, and Mental Privacy

Weekly Signal: 33 | Mind Captioning, Neural Barcodes, and Neurotech Ethics

Weekly Signal: 31 | FcRn Trials, Neuromodulation Breakthroughs, and Neuro-Rights

Weekly Signal: 29 | Synapses, Stimulators & Safeguards

The NeuroCircuit

NeuroCircuit